Alexander Choi, MD
Anatomic Pathology & Clinical Pathology · Brooklyn, NYNPI 1902238173
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.1% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $1,009, more than ten times the $26 reported in 2019. Among anatomic pathology & clinical pathology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 76 payments — averaging $29.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$471
- AbbVie$425
- Teva Pharmaceuticals USA, Inc.$398
- Medtronic$193
- Boston Scientific$161
- Merz Pharmaceuticals, LLC$144
- plus $415 from 11 others
What the payments were for
- Food & beverage$2,01091%
- Education$1979%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 13 | $471 |
| AbbVie(2 entities) | 20 | $425 |
| Teva Pharmaceuticals USA, Inc. | 8 | $398 |
| Medtronic | 3 | $193 |
| Boston Scientific | 4 | $161 |
| Merz Pharmaceuticals, LLC | 5 | $144 |
| Acorda Therapeutics, Inc | 8 | $138 |
| Amneal Pharmaceuticals LLC | 5 | $105 |
| Silvergate Pharmaceuticals, Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Cala Health, Inc. | 1 | $24 |
| Avion Pharmaceuticals | 1 | $21 |
| Corium, LLC | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUPLAZID$220
- GENERAL DBS$136
- AUSTEDO$122
- PERCEPT PC BRAINSENSE$120
- Duopa$101
How this compares
$2,207 in reported general payments places this provider in the 90th percentile of 468 anatomic pathology & clinical pathology providers in New York.
See all anatomic pathology & clinical pathology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 35 | $304,383 |
| Austedo XrDeutetrabenazine | 26 | $210,213 |
| NuplazidPimavanserin Tartrate | 25 | $124,599 |
| RytaryCarbidopa/Levodopa | 54 | $62,759 |
| GocovriAmantadine Hcl | 13 | $45,546 |
| NeuproRotigotine | 12 | $14,520 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 223 | $9,375 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 14 | $7,111 |
| MyrbetriqMirabegron | 11 | $5,082 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 43 | $4,338 |
| Rasagiline Mesylate | 33 | $3,657 |
| Rivastigmine | 21 | $2,803 |
| Selegiline Hcl | 26 | $2,755 |
| Gabapentin | 85 | $1,994 |
| AmantadineAmantadine Hcl | 41 | $1,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $16 | $304,38335 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $398 | $210,21326 claims |
| Acadia Pharmaceuticals IncNuplazid | $471 | $124,59925 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $105 | $63,57172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 468 anatomic pathology & clinical pathology providers in New York.
Other anatomic pathology & clinical pathology in Brooklyn
- Donelle CummingsBrooklyn$3K
- Jeffrey RossAlbany$110K
- Adebowale AdeniranNew York$106K
- Erin MarnerRochester$97K
- Leal HerlitzNew York$92K
- Shabnam JafferNew York$69K
- Judy SarungbamBronx$67K
- Zhi-Qiang Patrick HuFlushing$65K
- Hannah WenNew York$60K
- Soo Ryum YangNew York$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.